Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
Jennifer L. McQuade(The University of Texas MD Anderson Cancer Center), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Meredith McKean(Sarah Cannon), Kenneth R. Hess(The University of Texas MD Anderson Cancer Center), John M. Kirkwood(UPMC Hillman Cancer Center), Lauren E. Haydu(The University of Texas MD Anderson Cancer Center), Shenying Fang(The University of Texas MD Anderson Cancer Center), Christine N. Spencer(The University of Texas MD Anderson Cancer Center), Jeffrey E. Lee(The University of Texas MD Anderson Cancer Center), Alexander M. Menzies(The University of Sydney), Luna Musib, Keith T. Flaherty(Cancer Research Center), Douglas B. Johnson(Vanderbilt University Medical Center), Jeffrey J. Legos(Novartis (United States)), Edward McKenna(Roche (United Kingdom)), Carmen Mak(Novartis (United States)), Patrick Hwu(Moffitt Cancer Center), Dirk Schadendorf(National Center for Tumor Diseases), John Park(California Baptist University), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Stephen Lane(Novartis (United States)), Alexandre Avila(Bristol-Myers Squibb (United States)), T Haas(Novartis (United States)), Mäneka Puligandla(Dana-Farber Cancer Institute), Jean‐Jacques Grob(Aix-Marseille Université), Theodore S. Nowicki(QB3), Georgina V. Long(The University of Sydney), Kathryn E. Beckermann(Vanderbilt University Medical Center), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Carrie R. Daniel(The University of Texas MD Anderson Cancer Center), Nageshwar Budha, Jeffrey E. Gershenwald(The University of Texas MD Anderson Cancer Center), Matteo S. Carlino(The University of Sydney), Antoni Ribas(University of California, Los Angeles), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Daniel Wang(Vanderbilt University Medical Center), Samuel M. Rubinstein(University of North Carolina at Chapel Hill), Jessie J. Hsu, Mathilde Kaper(Novartis (United States)), Isabelle Rooney, Yibing Yan(Anhui Medical University), Matthew Wongchenko
Cited by 658
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k